NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma
MYELOMA CLINICAL TRIALS - Recruiting




- Sep 1, 2022
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM


- Sep 1, 2022
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1


- Sep 1, 2022
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma


- Jun 24, 2022
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma


- Jun 11, 2022
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM


- Jun 11, 2022
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma


- Jun 11, 2022
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T


- Jun 11, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma


- Jun 6, 2022
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM


- May 26, 2022
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation


- May 12, 2022
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma


- Apr 29, 2022
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant


- Apr 26, 2022
NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Myeloma & Lymphoma


- Apr 26, 2022
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release


- Apr 21, 2022
NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)


- Apr 20, 2022
NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT


- Apr 20, 2022
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM


- Apr 7, 2022
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7


- Apr 4, 2022
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets


- Apr 4, 2022
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM


- Mar 18, 2022
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex


- Mar 9, 2022
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant


- Mar 2, 2022
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM


- Mar 1, 2022
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)


- Mar 1, 2022
NCT05256446: AMG 701 Expanded Access Program


- Mar 1, 2022
NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma


- Mar 1, 2022
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)


- Mar 1, 2022
NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)


- Mar 1, 2022
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma


- Mar 1, 2022
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia


- Mar 1, 2022
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART


- Dec 29, 2021
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma


- Dec 23, 2021
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function


- Dec 20, 2021
NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)


- Dec 17, 2021
NCT05064358: Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)


- Dec 16, 2021
NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT


- Dec 16, 2021
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902


- Dec 16, 2021
NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM


- Dec 16, 2021
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)


- Dec 16, 2021
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma


- Dec 15, 2021
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART


- Dec 10, 2021
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia


- Dec 10, 2021
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab


- Dec 10, 2021
NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies


- Dec 8, 2021
NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma


- Dec 3, 2021
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3


- Dec 1, 2021
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide